SHIRE HUMAN GENETIC THERAPIES, INC.
LEXINGTON, MA

Shire Human Genetic Therapies, Inc. is a Florida-incorporated company headquartered at 300 Shire Way in Lexington, Massachusetts. Established on March 24, 2014, and categorized as a For-Profit Corporation (FORP), the company emphasizes transparency in its communications and business practices, focusing heavily on patient advocacy and collaboration with healthcare communities. The mission of Shire Human Genetic Therapies is to positively impact patients, patient organizations, and itself by ensuring that unique patient needs are well-understood and represented within the organization. The Patient Advocacy team serves as an internal voice aiming to understand and convey the emotional, financial, and day-to-day challenges faced by patients, caregivers, and families. Through strategic partnerships with patient advocacy groups, Shire aims to support disease education initiatives, enhance clinical trial awareness, and provide a presence at patient conferences. In its commitment to delivering better care and making differences in lives, Shire fosters an environment of continuous engagement with various healthcare stakeholders. As detailed on its official website, shirehumangenetictherapies.com, the company's latest event was recorded as reinstatement on September 9, 2024. Current leadership includes key officers and directors: Jason E. Baranski serving both as Secretary and Director, alongside Paul A. Sundberg in an Assistant role. With facilities located across multiple states including Massachusetts, Ohio, Ontario, Illinois, Michigan, New Jersey, Georgia, Texas, Kentucky, Virginia, Florida, Missouri, Brazil, Spain, and Ireland, Shire Human Genetic Therapies maintains a broad operational presence aligned with its global mission of enhancing patient lives through innovative genetic therapies.